Victor Perlroth, Kodiak Sciences CEO

Ko­di­ak man­ages to score a win for its Eylea ri­val — but the ma­jor test is still ahead

Ko­di­ak Sci­ences may have failed to show that its an­ti-VEGF drug is just as good as Re­gen­eron’s Eylea for wet AMD, but the biotech is keep­ing the pres­sure on.

In a new Phase III study in­volv­ing pa­tients with reti­nal vein oc­clu­sion (RVO) — a blind­ing con­di­tion that stems from vein block­age in the eye — KSI-301, which is dosed every two months, proved non-in­fe­ri­or in vi­su­al acu­ity gains to a month­ly reg­i­men of Eylea.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.